The antitumor antibiotic mithramycin: new advanced approaches in modification and production

Applied Microbiology and Biotechnology
Jan KormanecDagmar Homerova

Abstract

The aureolic acid-type polyketide mithramycin (MTM) has a remarkable cytotoxicity against a variety of human tumors and has been used for the treatment of several types of cancer, including chronic and acute myeloid leukemia, testicular carcinoma, hypercalcemia, and Paget's disease. However, its clinical use is quite limited due to its toxicity. Recently, interest in MTM has been renewed after its identification as a top candidate for the inhibition of the aberrant fusion transcription factor EWS-FLI1, associated with malignant transformation and progression of Ewing sarcoma tumor family. The mechanism of MTM inhibition involves its reversible non-intercalative interaction with GC-rich DNA regions. As a result of this binding, MTM blocks binding of transcription factors (such as Sp1) to their GC-rich promoters and inhibits transcription of several proto-oncogenes and thus suppresses various types of cancer. Knowledge of the biosynthesis of MTM and its gene cluster has enabled genetic modifications of the gene cluster and combinatorial biosynthesis to produce new modified MTM molecules ("mithralogues") with improved efficacy and lower toxicity, which has also renewed interest in the clinical development of MTM. However, producti...Continue Reading

References

Nov 1, 1987·The American Journal of the Medical Sciences·D M MillerC A Koller
Sep 1, 1995·Journal of Molecular Biology·M SastryD J Patel
May 1, 1995·Medical and Pediatric Oncology·B J Kennedy, J L Torkelson
Jul 6, 1993·Biochemistry·M Sastry, D J Patel
Jan 23, 1999·Journal of Natural Products·S E WohlertJ Rohr
Dec 20, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·N ZojerM Pecherstorfer
Feb 20, 2002·Chemical Reviews·David A. Hopwood
Jan 21, 1965·The New England Journal of Medicine·J H BROWN, B J KENNEDY
Jan 18, 2006·Journal of Biotechnology·Heinz G Floss
Oct 3, 2006·Applied Microbiology and Biotechnology·Felipe LombóCarmen Méndez
Feb 3, 2007·Natural Product Reports·Christian HertweckAndreas Bechthold
Jun 26, 2007·Bioscience, Biotechnology, and Biochemistry·Kozo Ochi
Jan 17, 2008·Journal of Natural Products·Irfan BaigJürgen Rohr
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Mamoru KomatsuHaruo Ikeda

❮ Previous
Next ❯

Citations

Feb 11, 2021·Applied Microbiology and Biotechnology·Dominika CsolleiovaJan Kormanec

❮ Previous
Next ❯

Methods Mentioned

BETA
NMR
xenograft
xenografts
glycosylation
PCR

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.